Kinugasa and colleagues (2015) analyzed serum KRAS (G12D, G12V and G12R) ctDNA mutations in 75 pancreatic cancer patients, with previously published KRAS mutations in a development cohort, and in 66 patients in an independent blinded validation cohort. Here, KRAS is linked to pancreatic neoplasm.